Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929254 | 0.92 | KDM4E (0.42) | KDM4EALDH1A1CD274PDCD1KMT2A | |
| SCHEMBL5929326 | 0.91 | KDM4E (0.44) | KDM4EALDH1A1CD274PDCD1KMT2A | |
| SCHEMBL5929168 | 0.89 | KMT2A (0.39) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5929006 | 0.86 | IL33 (0.41) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5928936 | 0.85 | KDM4E (0.46) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL5929150 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1CD274PDCD1KMT2A | |
| SCHEMBL5928975 | 0.81 | CNR1 (0.37) | KDM4ECD274PDCD1KMT2AMEN1 | |
| SCHEMBL5929107 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1CD274PDCD1KMT2A | |
| SCHEMBL5929230 | 0.80 | POLB (0.39) | KDM4EALDH1A1CD274PDCD1KMT2A | |
| SCHEMBL5929011 | 0.79 | KMT2A (0.38) | KDM4EALDH1A1CD274PDCD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | KDM4E 1762/4885ALDH1A1 3884/4885CD274 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.